Escitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults

Garnock-Jones, Karly P.; McCormack, Paul L.
September 2010
CNS Drugs;2010, Vol. 24 Issue 9, p769
Academic Journal
Escitalopram (escitalopram oxalate; Cipralex®, Lexapro®), a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD), demonstrates a highly selective and potent, dose-dependent inhibition of the human serotonin transporter, inhibiting serotonin reuptake into presynaptic nerve terminals and thus increasing serotonergic activity in the CNS. With regard to primary endpoints (such as improved scores on the Montgomery-Asberg Depression Rating Scale [MADRS] and the Hamilton Depression Rating Scale [HAM-D]) escitalopram was generally more effective than placebo, at least as effective as citalopram, and generally at least as effective as other comparator drugs, including the SSRIs fluoxetine, paroxetine and sertraline, the serotonin-noradrenaline (norepinephrine) reuptake inhibitors (SNRIs) venlafaxme extended release and duloxetine, and the aminoketone bupropion in adult patients with MDD in short-term, well designed trials. Moreover, it demonstrated a rapid onset of antidepressant action. Escitalopram was also found to be cost effective in several studies, dominating other SSRIs and venlafaxine extended release. Maintenance therapy is commonly required to prevent recurrence of depression. Long-term trials corroborated short-term results, with escitalopram demonstrating greater efficacy than placebo in relapse prevention. Additionally, escitalopram was at least as effective as citalopram, paroxetine and duloxetine in long-term comparative trials. Escitalopram has a predictable tolerability profile with generally mild to moderate and transient adverse events, and a low propensity for drug interactions. Sexual dysfunction with escitalopram treatment appeared to occur to a similar or lower extent to that with paroxetine (another SSRI), to a similar or greater extent to that with the SNRI duloxetine, and to a greater extent than that with the aminoketone bupropion. Thus, escitalopram is an effective and generally well tolerated treatment for moderate to severe MDD. Escitalopram, like other SSRIs, is an effective first-line option in the management of patients with MDD.


Related Articles

  • A Systematic Review of Antidepressant Placebo-Controlled Trials for Geriatric Depression: Limitations of Current Data and Directions for the Future. Taylor, Warren D.; Doraiswamy, P. Mural // Neuropsychopharmacology;Dec2004, Vol. 29 Issue 12, p2285 

    Depression in the elderly is a major public health problem as untreated depression adversely impacts comorbid illnesses. It is important to develop safe and effective antidepressant therapies for older individuals. We performed a systematic review of all published randomized, placebo-controlled...

  • SSRIs start to relieve depression soon after the start of treatment.  // BMJ: British Medical Journal (International Edition);12/9/2006, Vol. 333 Issue 7580, p1180 

    The article examines how long it takes for selective serotonin reuptake inhibitors (SSRIs) to relieve depression and focuses on a study which looked at published clinical trials that compared SSRI antidepressants with placebo for depressed patients. The authors found that antidepressants work...

  • Escitalopram: In the Treatment of Major Depressive Disorder in Adolescent Patients. Lily P.H. Yang; Scott, Lesley J. // Pediatric Drugs;2010, Vol. 12 Issue 3, p155 

    Escitalopram is a selective serotonin reuptake inhibitor (SSRI), and is the second antidepressant to be approved for use in treating major depressive disorder (MDD) in adolescent patients (aged 12-17 years) in the US. In a randomized, double-blind, flexible-dose, multicenter trial, once-daily...

  • Emsam.  // Formulary;Apr2006, Vol. 41 Issue 4, p170 

    The article focuses on the approval of selegiline transdermal patch from Bristol-Myers Squibb/Somerset for the treatment of major depressive disorder. Patients receiving selegiline via the transdermal patch experienced a longer time to relapse than did those receiving placebo during the...

  • Disparate findings on a link between SSRIs and suicide. Paist, Scott S.; Russell, John J. // Patient Care;May2005, Vol. 39 Issue 5, p62 

    Presents information on two articles about the occurrences of suicide and intentional self-harm following the initiation of selective serotonin reuptake inhibitor (SSRI) therapy for depression. "Selective Serotonin Reuptake Inhibitors and Suicide in Adults: Meta-analysis of Drug Company Data...

  • The impact of missing data on clinical trials: a re-analysis of a placebo controlled trial of Hypericum perforatum (St Johns wort) and sertraline in major depressive disorder. Grobler, Anneke; Matthews, Glenda; Molenberghs, Geert // Psychopharmacology;May2014, Vol. 231 Issue 9, p1987 

    Rationale and objective: Hypericum perforatum (St John's wort) is used to treat depression, but the effectiveness has not been established. Recent guidelines described the analysis of clinical trials with missing data, inspiring the reanalysis of this trial using proper missing data methods. The...

  • Drug Treatments for Patients with Dysthymia. Kripke, Clarissa // American Family Physician;10/1/2004, Vol. 70 Issue 7, p1269 

    Presents information on drug treatments that are effective for dysthymia. Comparison between the efficacy of anti-depressants and placebo; Information on the side effects of tricyclic antidepressants and selective serotonin reuptake inhibitors.

  • Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Peet, Malcolm; Peet, M // British Journal of Psychiatry;Apr94, Vol. 164, p549 

    The rate of treatment-emergent switch into mania has been calculated from all available clinical trial data on the selective serotonin re-uptake inhibitors (SSRIs) fluoxetine, fluvoxamine, paroxetine, and sertraline, relative to comparative groups treated with tricyclic antidepressants (TCAs) or...

  • Mirtazapine. A pharmacoeconomic review of its use in depression. Holm, K.J.; Jarvis, B.; Foster, R.H. // PharmacoEconomics;2000, Vol. 17 Issue 5, p515 

    Unlabelled: Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA). The antidepressant efficacy of mirtazapine has been established in randomised, double-blind comparative studies. Mirtazapine has generally shown similar efficacy to other antidepressants....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics